Abbott’s SonicForce recorded just 0.3% lesion failure, but can it challenge Shockwave in coronary calcium treatment?
Abbott has reported 97% procedural success and 0.3% target lesion failure at 30 days in its 335-patient TECTONIC study of SonicForce. The findings support the investigational system's regulatory development, although the single-arm trial does not establish superiority over existing coronary lithotripsy devices.